Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Drucker

Showing results (121-130 of 549) with videos related to

Pageof 55
Sort By:
Nature Reviews. Endocrinology|April 9, 2015
Islet α cells and glucagon--critical regulators of energy homeostasisJonathan E Campbell, Daniel J Drucker
Immunity|October 4, 2025
Obesity, diabetes, and inflammation: Pathophysiology and clinical implicationsMarc Y Donath, Daniel J Drucker
Endocrine Pathology|May 7, 2020
Transgenic mice in the study of endocrine systemsRobert V Campos, Daniel J Drucker
Diabetes|April 29, 2006
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cellsJacqueline A Koehler, Daniel J Drucker
Endocrinology|December 17, 2004
Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosaJennifer L Estall, Daniel J Drucker
Lancet (London, England)|February 15, 2011
Cardiovascular safety and diabetes drug developmentDaniel J Drucker, Allison B Goldfine
Presse Medicale (Paris, France : 1983)|March 17, 1984
[C-reactive protein of the cerebrospinal fluid in children. A new evaluation of its diagnostic value]S Marchand, B Grenier, J Drucker
Endocrine Reviews|September 13, 2014
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitorsErin E Mulvihill, Daniel J Drucker
Gastroenterology|May 15, 2007
Biology of incretins: GLP-1 and GIPLaurie L Baggio, Daniel J Drucker
Lancet (London, England)|November 14, 2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesDaniel J Drucker, Michael A Nauck
Pageof 55

Showing results (121-130 of 549) with videos related to

Sort By:
Pageof 55
Nature Reviews. Endocrinology|April 9, 2015
Islet α cells and glucagon--critical regulators of energy homeostasisJonathan E Campbell, Daniel J Drucker
Immunity|October 4, 2025
Obesity, diabetes, and inflammation: Pathophysiology and clinical implicationsMarc Y Donath, Daniel J Drucker
Endocrine Pathology|May 7, 2020
Transgenic mice in the study of endocrine systemsRobert V Campos, Daniel J Drucker
Diabetes|April 29, 2006
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cellsJacqueline A Koehler, Daniel J Drucker
Endocrinology|December 17, 2004
Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosaJennifer L Estall, Daniel J Drucker
Lancet (London, England)|February 15, 2011
Cardiovascular safety and diabetes drug developmentDaniel J Drucker, Allison B Goldfine
Presse Medicale (Paris, France : 1983)|March 17, 1984
[C-reactive protein of the cerebrospinal fluid in children. A new evaluation of its diagnostic value]S Marchand, B Grenier, J Drucker
Endocrine Reviews|September 13, 2014
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitorsErin E Mulvihill, Daniel J Drucker
Gastroenterology|May 15, 2007
Biology of incretins: GLP-1 and GIPLaurie L Baggio, Daniel J Drucker
Lancet (London, England)|November 14, 2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesDaniel J Drucker, Michael A Nauck
Pageof 55